A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2011-2012, When Administered to Elderly Subjects.
Latest Information Update: 30 Apr 2023
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 23 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Apr 2011 New trial record